Radioiodine treatment of well-differentiated thyroid cancer

作者: Leonard Wartofsky , Douglas Van Nostrand

DOI: 10.1007/S12020-012-9729-5

关键词:

摘要: Ablation refers to the first administration of radioiodine a patient with WDTC. Usually, this dose is administered within 4–6 weeks after total thyroidectomy. Because some thyroid tissue usually present in neck even thyroidectomy, optimal follow-up achieved following ablation or destruction normal residual tissue. Other objectives are discussed below “Objectives and treatment” section. The term “Treatment” applies subsequently, when there evidence distinction definitions aids physician communication therapeutic interventions. While most endocrinologists use “dosage” apply amount administered, more appropriate “activity”. Rather, “dosage,” should be used express radiation absorbed rads grays patient.

参考文章(48)
Richard J. Robbins, R. Michael Tuttle, Martin Sonenberg, Ashok Shaha, Renu Sharaf, Heather Robbins, Martin Fleisher, Steven M. Larson, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. ,vol. 11, pp. 865- 869 ,(2001) , 10.1089/105072501316973127
Furio Pacini, Martin Schlumberger, Henning Dralle, Rossella Elisei, Johannes WA Smit, Wilmar Wiersinga, European Thyroid Cancer Taskforce, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium European Journal of Endocrinology. ,vol. 154, pp. 787- 803 ,(2006) , 10.1530/EJE.1.02158
Elif Hindié, Didier Mellière, Françoise Lange, Iyad Hallaj, Claire de Labriolle-Vaylet, Christian Jeanguillaume, Jacques Lange, Léon Perlemuter, Serge Askienazy, Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 30, pp. 974- 981 ,(2003) , 10.1007/S00259-003-1174-5
Keith Pentlow, R. Michael Tuttle, Richard J. Robbins, Rebecca Qualey, Rebecca Leboeuf, Steven M. Larson, Chee Y. Chan, Empiric Radioactive Iodine Dosing Regimens Frequently Exceed Maximum Tolerated Activity Levels in Elderly Patients with Thyroid Cancer The Journal of Nuclear Medicine. ,vol. 47, pp. 1587- 1591 ,(2006)
Shirley Mallette, Patti Eyre, William H. Beierwaltes, Ricardo V. Lloyd, Roya Rabbani, Carl Dmuchowski, An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. The Journal of Nuclear Medicine. ,vol. 25, pp. 1287- 1293 ,(1984)
Harry R. Maxon, Stephen R. Thomas, Vicki S. Hertzberg, James G. Kereiakes, I-Wen Chen, Matthew I. Sperling, Eugene L. Saenger, Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid Cancer The New England Journal of Medicine. ,vol. 309, pp. 937- 941 ,(1983) , 10.1056/NEJM198310203091601
Paul W. Ladenson, Lewis E. Braverman, Ernest L. Mazzaferri, Françoise Brucker-Davis, David S. Cooper, Jeffrey R. Garber, Fredric E. Wondisford, Terry F. Davies, Leslie J. DeGroot, Gilbert H. Daniels, Douglas S. Ross, Bruce D. Weintraub, Ian D. Hay, Silvina Levis, James C. Reynolds, Jacob Robbins, David V. Becker, Ralph R. Cavalieri, Harry R. Maxon, Kevin McEllin, Richard Moscicki, Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma The New England Journal of Medicine. ,vol. 337, pp. 888- 896 ,(1997) , 10.1056/NEJM199709253371304
George Sgouros, Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. The Journal of Nuclear Medicine. ,vol. 34, pp. 689- 694 ,(1993)
Primum non nocere The Lancet. ,vol. 344, pp. 1487- 1488 ,(1994) , 10.1016/S0140-6736(94)90296-8
N R Cicale, R W Rawson, M Sonenberg, R S Benua, The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. American Journal of Roentgenology. ,vol. 87, pp. 171- 182 ,(1962)